2022 Year in Review - Cholangiocarcinoma

Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection. Read More ›

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival. Read More ›

A systematic review of phase 2 and 3 clinical trials for biliary tract cancers revealed quality-of-life assessments were not routinely included as trial outcomes. Read More ›

The phase 2 STAMP study revealed negligible differences in disease-free survival and overall survival between adjuvant gemcitabine/cisplatin versus capecitabine in lymph node–positive extrahepatic cholangiocarcinoma but found increased grade 3/4 adverse events with gemcitabine/cisplatin. Read More ›

Investigators found the addition of toripalimab to a gemcitabine-based chemotherapy regimen as first-line treatment of advanced biliary tract cancers demonstrated encouraging efficacy. Read More ›

A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma. Read More ›

Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma. Read More ›

Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy. Read More ›

Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control. Read More ›

The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer. Read More ›